Escalier Biosciences develops topical and oral RORγt-based therapeutics for treatment of psoriasis and other autoimmune diseases
Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target RORyt for the treatment of psoriasis and other autoimmune disorders.
The nuclear hormone receptor RORγt has emerged as the “master” regulator of Th17 cell differentiation and the production of pro-inflammatory cytokines, such as IL-17, which has been linked to the pathophysiology of psoriasis and other autoimmune diseases. Small molecule inhibitors of RORγt have been shown to reduce production of IL-17 in immune cells and are promising therapies for psoriasis and other autoimmune conditions. Escalier’s lead topical and oral drug candidates will enter clinical studies in 2018. Escalier is registered in The Netherlands with offices in Nijmegen, The Netherlands and Encinitas, California.
- CEO Raju Mohan, PhD
- Industry Biotech